Presentation on theme: "HeartWare® Ventricular Assist System"— Presentation transcript:
1HeartWare® Ventricular Assist System Patient Selection
2Objectives Identify patients that may benefit from VAD support Discuss clinical indicators associated with higher morbidity and mortality in VAD patientsProvide an overview of indications and contraindications for the HeartWare® System
3Natural History of Heart Failure Adapted from Bristow, MR Management of Heart Failure, Heart Disease: A Textbook of Cardiovascular Medicine, 6th edition, ed. Braunwald et al.Overall, 50% of HF patients are dead at 4 years, and 40% of patients hospitalized with HF are dead or readmitted within 1 year.1Most patients would consider LVAD therapy when presented with a scenario of end-stage heart failure1Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure Eur Heart J. 2008; 29:
4Transplant as an Option for Advanced Heart Failure 19822008UNOS data:17% of patients on the waiting list for a heart died48% of patients had spent more than 2 years on the wait list1J Heart Lung Transplant Oct; 29 (10):Heart transplant is an option, however, limited donor availability is an issue21 Lietz K and Miller L. J Am Coll Cardiol 2007;50:1282–902 ISHLT Website
5INTERMACS – Estimated 1-Year Survival European Journal of Heart Failure (2010) 12, doi: /eurjhf/hfq006
6Predictors of Mortality in Patients with Heart Failure NYHA Functional CapacityExercise Testing – pVO2Exercise VO2 is an objective way to measure exercise tolerance, and perhaps predict mortality with heart failureVO2 <14ml/kg/min high predictor of mortality; 1-yr survival (47%) 2-yr survival (32%) 3A strong association between NYHA class and outcomes in patients with systolic heart failure has been consistently reported in the literature1Both NYHA classification and peak VO2 are significantly associated with survival time in patients with mild to moderate CHF, but peak VO2 subdivides patients more clearly into subgroups according to the severity of functional impairment and lifetime prognosis.21Ahmed, et al, (2006). Higher New York Heart Association Classes and Increased Mortality and Hospitalization in Heart Failure Patients with Preserved Left Ventricular Function, Am Heart Journal 2006 February; 151(2):2 Broek, et al. Comparison between New York Heart Association Classification and peak oxygen consumption in the assessment of functional status and prognosis in patients with mild to moderate chronic congestive heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. The American Journal of Cardiology, 1992; 70(3): Mancini, et al, Circulation, 1991
7Considerations of VAD Therapy Potentially reversible cause of heart failureRecent or evolving strokeNeurological deficits impairing the ability to manage deviceCoexisting terminal condition (e.g., metastatic cancer, cirrhosis)Abdominal aortic aneurysm > 5 cmSymptomatic right heart failureActive systemic infection or major chronic risk for infectionFixed pulmonary hypertensionSevere pulmonary dysfunction (e.g., FEV1<1 L)Current or impending renal or hepatic failureMultisystem organ failureHeparin-induced thrombocytopeniaSignificant underlying psychiatric illness or lack of social support
8Considerations for Surgical Implant Aortic and/or tricuspid insufficiency or mitral stenosisPre-existing mechanical valvesIntracardiac shunts
9HeartWare® System Indications for Use The HeartWare Ventricular Assist System is intended for use as a bridge to cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failureThe HeartWare System is designed for in-hospital and out-of-hospital settings, including transportation via fixed wing aircraft or helicopterWARNING! Serious and life threatening adverse events, including stroke, have been associated with use of this device. A user must fully consider the risks of this device with that of other treatment modalities before deciding to proceed with device implantation.
10HeartWare® System Contraindications The HeartWare System is contraindicated in patients who cannot tolerate anticoagulation therapy.WARNING! Do not use in pregnant women. Any women receiving the HeartWare System who is of child bearing age should use a reliable method of birth control.CAUTION: Safety and effectiveness in persons less than 18 years of age and in persons with a BSA of less than 1.5m2 have not been established.CAUTION: The HeartWare Ventricular Assist System has had limited use in patients with artificial mitral or aortic valves and therefore the risks are currently unknown.
11SummaryThe natural history of heart failure leads to multiple hospitalizations, worsening symptoms, use of IV inotropic medications and eventually to orthotopic heart transplantation for those that are eligibleA lack of organs for transplant has led to longer wait times and therefore significant mortality risk for those waitingThe HeartWare System is an option to bridge patients to heart transplantTiming and patient selection, although still being studied in continuous flow devices, are essential to continued optimal outcomes and reduction of mortality
12ReferencesKormos RL, Teuteberg JJ, Pagani FD, Russell SD, John R, Miller LW, Massey T, Milano CA, Moazami N, Sundareswaran KS, Farrar DJ; HeartMate II Clinical Investigators. Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: incidence, risk factors, and effect on outcomes. J Thorac Cardiovasc Surg May;139(5):Lund LH, Matthews J, Aaronson K. Patient selection for left ventricular assist devices. Eur J Heart Fail May; 12(5):Sasaki H, Mitchell JD, Jessen ME, Lavingia B, Kaiser PA, Comeaux A, Dimaio JM, Meyer DM. Bridge to heart transplantation with left ventricular assist device versus inotropic agents in status 1 patients. J Card Surg Nov-Dec; 24(6):Kwon MH, Moriguchi JD, Ardehali A, Jocson R, Marelli D, Laks H, Shemin RJ, Esmailian F. Use of ventricular assist device as a bridge to cardiac transplantation: impact of age and other determinants on outcomes. Tex Heart Inst J. 2009; 36(3):214-9.Lietz K, Miller LW. Patient selection for left-ventricular assist devices. Curr Opin Cardiol May;24(3): Review.Holman WL, Pae WE, Teutenberg JJ, Acker MA, Naftel DC, Sun BC, Milano CA, Kirklin JK. INTERMACS: interval analysis of registry data. J Am Coll Surg May; 208(5):755-61; discussionWilson SR, Mudge GH Jr, Stewart GC, Givertz MM. Evaluation for a ventricular assist device: selecting the appropriate candidate. Circulation Apr 28;119(16): Review.
13ReferencesSandner SE, Zimpfer D, Zrunek P, Rajek A, Schima H, Dunkler D, Grimm M, Wolner E, Wieselthaler GM. Renal function and outcome after continuous flow left ventricular assist device implantation. Ann Thorac Surg Apr; 87(4):Schulman AR, Martens TP, Russo MJ, Christos PJ, Gordon RJ, Lowy FD, Oz MC, Naka Y. Effect of left ventricular assist device infection on post-transplant outcomes. J Heart Lung Transplant Mar; 28(3):Levy WC, Mozaffarian D, Linker DT, Farrar DJ, Miller LW; REMATCH Investigators. Can the Seattle heart failure model be used to risk-stratify heart failure patients for potential left ventricular assist device therapy? J Heart Lung Transplant Mar;28(3):231-6.Holman WL, Kormos RL, Naftel DC, Miller MA, Pagani FD, Blume E, Cleeton T, Koenig SC, Edwards L, Kirklin JK. Predictors of death and transplant in patients with a mechanical circulatory support device: a multi-institutional study. J Heart Lung Transplant Jan; 28(1):44-50.Rao V, Oz MC, Flannery MA, Catanese KA, Argenziano M, Naka Y. Revised screening scale to predict survival after insertion of a left ventricular assist device. J Thorac Cardiovasc Surg Apr;125(4):Miller LW. Patient selection for the use of ventricular assist devices as a bridge to transplantation. Ann Thorac Surg Jun;75(6 Suppl):S Review.Ahmed, et al, (2006). Higher New York Heart Association Classes and Increased Mortality and Hospitalization in Heart Failure Patients with Preserved Left Ventricular Function, Am Heart Journal 2006 February; 151(2):Broek, et al. Comparison between New York Heart Association Classification and peak oxygen consumption in the assessment of functional status and prognosis in patients with mild to moderate chronic congestive heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. The American Journal of Cardiology, 1992; 70(3):HeartWare® Ventricular Assist System, Instructions for Use